Literature DB >> 27933688

Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis.

K Hartery1,2, S O'Reilly1,2, D Houlihan2,3, G Doherty1,2, H Mulcahy1,2, G Cullen1,2, J Sheridan1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27933688     DOI： 10.1111/apt.13861

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  3 in total

1.  Safety of vedolizumab in liver transplant recipients: A systematic review.

Authors:  Marco Spadaccini; Alessio Aghemo; Flavio Caprioli; Ana Lleo; Federica Invernizzi; Silvio Danese; Maria F Donato
Journal:  United European Gastroenterol J       Date:  2019-06-20       Impact factor: 4.623

2.  Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.

Authors:  Mohamad A Mouchli; Siddharth Singh; Lisa Boardman; David H Bruining; Amy L Lightner; Charles B Rosen; Julie K Heimbach; Bashar Hasan; John J Poterucha; Kymberly D Watt; Sunanda V Kane; Laura E Raffals; Edward V Loftus
Journal:  Inflamm Bowel Dis       Date:  2018-04-23       Impact factor: 5.325

Review 3.  Specific Features of Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.

Authors:  Fotios S Fousekis; Vasileios I Theopistos; Ioannis V Mitselos; Alexandros Skamnelos; Athanasios Kavvadias; Konstantinos H Katsanos; Dimitrios K Christodoulou
Journal:  J Clin Med Res       Date:  2019-01-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.